Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.

Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Abstract Text:

    baorui liuBaorui Liu,jia weiJia Wei,zhengyun zouZhengyun Zou,xiaoping qianXiaoping Qian,takahiro nakamuraTakahiro Nakamura,wei zhangWei Zhang,yitao dingYitao Ding,jifeng fengJifeng Feng,lixia yuLixia Yu,

    Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens. Platinum agents have shown to be effective in the treatment of gastric cancer. We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. SNPs of XPD-751, XRCC1-399 and GSTP1-105 in 62 gastric cancer patients were evaluated using the TaqMan 5' nuclease assay. Genotypes were correlated to survival. The median overall survival time was 322 days (range: 56-2058 days). The median survival times for patients with Arg/Arg or Arg/Gln genotypes of XRCC1 gene were significantly longer than others (P=0.03). For 58 patients with ECOG PS (Eastern Cooperative Oncology Group performance status)

    Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Publishing Authors By Initials

    b liuB Liu,j weiJ Wei,z zouZ Zou,x qianX Qian,t nakamuraT Nakamura,w zhangW Zhang,y dingY Ding,j fengJ Feng,l yuL Yu,

    For similar enzymes and coenzymes: enzymes: hydrolases: acid anhydride hydrolases: adenosine triphosphatases: dna helicases: xeroderma pigmentosum group d protein research abstracts see: enzymes and coenzymes: enzymes: hydrolases: acid anhydride hydrolases: adenosine triphosphatases: dna helicases: xeroderma pigmentosum group d protein research

    PUBMED ID PMID:

    MEDLINE DATE:

    Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: European journal of human genetics : EJHG

    VOLUME: 15

    Page Numbers: 1049-53

    Journal Abbreviation: Eur. J. Hum. Genet.

    ISSN: 1018-4813

    DAY: 27

    MONTH: 06

    YEAR: 2007

    Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9302235

    Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Keywords Mesh Terms:

    KEYWORDS: Xeroderma Pigmentosum Group D Protein

    MESH TERMS: genetics

    Chemical & Substance for Abstract: Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Information

    Substance Name: Xeroderma Pigmentosum Group D Protein

    Registry Number: EC 5.99.-

    Grant and Affiliation Information for Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.

    AFFILIATION: Department of Oncology, Drum Tower Hospital (affiliated to Medical School of Nanjing University) and Clinical Cancer Institute of Nanjing University, Nanjing, China. baoruiliu@nju.edu.cn

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Eur J Hum Genet

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News